Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Cytomegalovirus Infection

  Free Subscription


Articles published in J Infect Dis

Retrieve available abstracts of 47 articles:
HTML format



Single Articles


    July 2021
  1. HAMILTON EM, Allen NE, Mentzer AJ, Littlejohns TJ, et al
    Human cytomegalovirus and risk of incident cardiovascular disease in UK Biobank.
    J Infect Dis. 2021 Jul 19. pii: 6323934. doi: 10.1093.
    PubMed     Abstract available


  2. POLONI C, Szyf M, Cheishvili D, Tsoukas CM, et al
    Are the healthy vulnerable? Cytomegalovirus seropositivity in healthy adults is associated with accelerated epigenetic age and immune-dysregulation.
    J Infect Dis. 2021 Jul 13. pii: 6320592. doi: 10.1093.
    PubMed     Abstract available


    April 2021
  3. STERN A, Su Y, Dumke H, Fang J, et al
    CMV viral load kinetics predict CMV end-organ disease and mortality after hematopoietic cell transplant (HCT).
    J Infect Dis. 2021 Apr 17. pii: 6232014. doi: 10.1093.
    PubMed     Abstract available


  4. DIOVERTI PRONO MV, Avery RK
    Viral load kinetics: a way to assess cumulative effects of CMV on hematopoietic stem cell transplant recipients.
    J Infect Dis. 2021 Apr 17. pii: 6232022. doi: 10.1093.
    PubMed    


    March 2021
  5. SINGH N, Winston DJ, Razonable RR, Lyon GM, et al
    Unexpected CMV replication kinetics in CMV- donor seropositive recipient seronegative liver transplant recipients receiving preemptive antiviral therapy.
    J Infect Dis. 2021 Mar 23. pii: 6182482. doi: 10.1093.
    PubMed     Abstract available


    December 2020
  6. ALTAF M, Lineburg K, Crooks P, Rehan S, et al
    Pre-transplant cytomegalovirus-specific cellular immunity and risk of viral reactivation following lung transplantation: a prospective cohort study.
    J Infect Dis. 2020 Dec 4. pii: 6019998. doi: 10.1093.
    PubMed     Abstract available


    November 2020
  7. DONADEU L, Revilla-Lopez E, Jarque M, Crespo E, et al
    CMV-specific Cell-Mediated Immunity Predicts High level of CMV Replication after Prophylaxis withdrawal in Lung Transplant Recipients.
    J Infect Dis. 2020 Nov 27. pii: 6007492. doi: 10.1093.
    PubMed     Abstract available


  8. IMLAY H, Dasgupta S, Boeckh M, Stapleton RD, et al
    Risk Factors for Cytomegalovirus Reactivation and Association with Outcomes in Critically Ill Adults with Sepsis: A Pooled Analysis of Prospective Studies.
    J Infect Dis. 2020 Nov 7. pii: 5959850. doi: 10.1093.
    PubMed     Abstract available


    October 2020
  9. SLYKER JA, Guthrie B, Pankau M, Tapia K, et al
    Cytomegalovirus and Epstein-Barr virus viremia are associated with HIV DNA levels in the reservoir of Kenyan infants on antiretroviral therapy.
    J Infect Dis. 2020 Oct 16. pii: 5926738. doi: 10.1093.
    PubMed     Abstract available


  10. COX KS, Zhang L, Freed DC, Tang A, et al
    Functional Evaluation and Genetic Evolution of Human T-cell Responses after Vaccination with a Conditionally Replication-Defective Cytomegalovirus Vaccine.
    J Infect Dis. 2020 Oct 8. pii: 5919748. doi: 10.1093.
    PubMed     Abstract available


    September 2020
  11. NIKOLICH-ZUGICH J
    Cytomegalovirus and Your Health: Not a Matter of the Heart, Nor of Life and Death.
    J Infect Dis. 2020 Sep 10. pii: 5903620. doi: 10.1093.
    PubMed    


  12. CHEN S, Pawelec G, Trompet S, Goldeck D, et al
    Associations of Cytomegalovirus Infection With All-Cause and Cardiovascular Mortality in Multiple Observational Cohort Studies of Older Adults.
    J Infect Dis. 2020 Sep 10. pii: 5903621. doi: 10.1093.
    PubMed     Abstract available


    August 2020
  13. PAEZ-VEGA A, Cantisan S, Aguera ML, Suner M, et al
    Pretransplant CMV-specific T-cell immunity but not dose of antithymocyte globulin is associated with recovery of specific immunity after kidney transplantation.
    J Infect Dis. 2020 Aug 11. pii: 5890921. doi: 10.1093.
    PubMed     Abstract available


    July 2020
  14. SINGH N, Winston DJ, Razonable RR, Lyon GM, et al
    Risk factors for viremia in CMV- recipient seronegative donor seropositive liver transplant recipients who receive preemptive antiviral therapy.
    J Infect Dis. 2020 Jul 29. pii: 5878043. doi: 10.1093.
    PubMed     Abstract available


  15. CHOU S, Song K, Wu J, Bo T, et al
    Drug resistance mutations and associated phenotypes detected in clinical trials of maribavir for treatment of cytomegalovirus infection.
    J Infect Dis. 2020 Jul 29. pii: 5877931. doi: 10.1093.
    PubMed     Abstract available


  16. HASING ME, Pang XL, Mabilangan C, Preiksaitis JK, et al
    Donor cytomegalovirus transmission patterns in solid organ transplant recipients with primary infection.
    J Infect Dis. 2020 Jul 24. pii: 5876001. doi: 10.1093.
    PubMed     Abstract available


  17. VIETZEN H, Gorzer I, Honsig C, Jaksch P, et al
    Human Cytomegalovirus (HCMV)-Specific Antibody Response and Development of Antibody-Dependent Cellular Cytotoxicity Against HCMV After Lung Transplantation.
    J Infect Dis. 2020;222:417-427.
    PubMed     Abstract available


  18. KAMINSKI H, Menard C, El Hayani B, Adjibabi AN, et al
    Characterization of a unique gammadelta T cell subset as a specific marker of CMV infection severity.
    J Infect Dis. 2020 Jul 5. pii: 5867506. doi: 10.1093.
    PubMed     Abstract available


    April 2020
  19. SCHWENDINGER M, Thiry G, De Vos B, Leroux-Roels G, et al
    A Randomized Dose-Escalating Phase I Trial of a Replication-Deficient Lymphocytic Choriomeningitis Virus Vector-Based Vaccine Against Human Cytomegalovirus.
    J Infect Dis. 2020 Apr 21. pii: 5821369. doi: 10.1093.
    PubMed     Abstract available


  20. ALI A, Chiuppesi F, Nguyen M, Hausner MA, et al
    Chimeric Antigen Receptors Targeting Human Cytomegalovirus.
    J Infect Dis. 2020 Apr 13. pii: 5819787. doi: 10.1093.
    PubMed     Abstract available


    March 2020
  21. IMLAY H, Limaye AP
    Current Understanding of Cytomegalovirus Reactivation in Critical Illness.
    J Infect Dis. 2020;221.
    PubMed     Abstract available


  22. LAUGHLIN C, Chakhtoura N, Beisel C, Dempsey W, et al
    Cytomegalovirus Meeting Summary.
    J Infect Dis. 2020;221.
    PubMed    


  23. RAZONABLE RR, Inoue N, Pinninti SG, Boppana SB, et al
    Clinical Diagnostic Testing for Human Cytomegalovirus Infections.
    J Infect Dis. 2020;221.
    PubMed     Abstract available


  24. HAIDAR G, Boeckh M, Singh N
    Cytomegalovirus Infection in Solid Organ and Hematopoietic Cell Transplantation: State of the Evidence.
    J Infect Dis. 2020;221.
    PubMed     Abstract available


  25. KRAUSE PR, Roberts J
    Scientific and Regulatory Considerations for Efficacy Studies of Cytomegalovirus Vaccines.
    J Infect Dis. 2020;221.
    PubMed     Abstract available


  26. PLOTKIN SA
    Preventing Infection by Human Cytomegalovirus.
    J Infect Dis. 2020;221.
    PubMed     Abstract available


  27. ACOSTA E, Bowlin T, Brooks J, Chiang L, et al
    Advances in the Development of Therapeutics for Cytomegalovirus Infections.
    J Infect Dis. 2020;221.
    PubMed     Abstract available


  28. MUSSI-PINHATA MM, Yamamoto AY
    Natural History of Congenital Cytomegalovirus Infection in Highly Seropositive Populations.
    J Infect Dis. 2020;221.
    PubMed     Abstract available


  29. ROARK HK, Jenks JA, Permar SR, Schleiss MR, et al
    Animal Models of Congenital Cytomegalovirus Transmission: Implications for Vaccine Development.
    J Infect Dis. 2020;221.
    PubMed     Abstract available


  30. KABANI N, Ross SA
    Congenital Cytomegalovirus Infection.
    J Infect Dis. 2020;221.
    PubMed     Abstract available


  31. BRITT WJ
    Human Cytomegalovirus Infection in Women With Preexisting Immunity: Sources of Infection and Mechanisms of Infection in the Presence of Antiviral Immunity.
    J Infect Dis. 2020;221.
    PubMed     Abstract available


  32. PLOTKIN SA, Wang D, Oualim A, Diamond DJ, et al
    The Status of Vaccine Development Against the Human Cytomegalovirus.
    J Infect Dis. 2020;221.
    PubMed     Abstract available


  33. NELSON CS, Baraniak I, Lilleri D, Reeves MB, et al
    Immune Correlates of Protection Against Human Cytomegalovirus Acquisition, Replication, and Disease.
    J Infect Dis. 2020;221.
    PubMed     Abstract available


  34. HODOWANEC AC, Pikis A, Singer ME
    The Development of Therapeutics for the Treatment and Prevention of CMV Disease in the Transplant Population: A Regulatory Perspective.
    J Infect Dis. 2020;221.
    PubMed     Abstract available


  35. LANZIERI TM, Gastanaduy PA, Gambhir M, Plotkin SA, et al
    Review of Mathematical Models of Vaccination for Preventing Congenital Cytomegalovirus Infection.
    J Infect Dis. 2020;221.
    PubMed     Abstract available


  36. GRIFFITHS P, Hughes B
    Choice of Study Populations for Vaccines.
    J Infect Dis. 2020;221.
    PubMed     Abstract available


    February 2020
  37. BEHRENS GA, Brehm M, Gross R, Heider J, et al
    Non-invasive determination of CMV serostatus from dried buccal swab samples: assay development, validation and application to 1.2 million samples.
    J Infect Dis. 2020 Feb 13. pii: 5735315. doi: 10.1093.
    PubMed     Abstract available


    December 2019
  38. JO H, Kwon DE, Han SH, Min SY, et al
    De Novo Genotypic Heterogeneity in the UL56 Region in Cytomegalovirus-infected Tissues: Implications for Primary Letermovir Resistance.
    J Infect Dis. 2019 Dec 5. pii: 5658434. doi: 10.1093.
    PubMed     Abstract available


    November 2019
  39. JAMES SH
    Letermovir Resistance in Hematopoietic Stem Cell Transplant Recipients: The Risks Associated with Cytomegalovirus Prophylaxis.
    J Infect Dis. 2019 Nov 29. pii: 5645460. doi: 10.1093.
    PubMed    


  40. DOUGLAS CM, Barnard R, Holder D, Leavitt R, et al
    Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients.
    J Infect Dis. 2019 Nov 29. pii: 5645458. doi: 10.1093.
    PubMed     Abstract available


  41. ZAMORA D, Krantz EM, Green ML, Joncas-Schronce L, et al
    The Cytomegalovirus Humoral Response Against Epithelial Cell Entry-mediated Infection in the Primary Infection Setting after Hematopoietic Cell Transplantation.
    J Infect Dis. 2019 Nov 18. pii: 5627782. doi: 10.1093.
    PubMed     Abstract available


  42. SMITH C, Moraka NO, Ibrahim M, Moyo S, et al
    HIV Exposure but Not Early CMV Infection is Associated with Increased Hospitalization and Decreased Memory T-cell Responses to Tetanus Vaccine.
    J Infect Dis. 2019 Nov 10. pii: 5618838. doi: 10.1093.
    PubMed     Abstract available


  43. STOCKDALE L, Nash S, Farmer R, Raynes J, et al
    Cytomegalovirus antibody responses associated with increased risk of TB disease in Ugandan adults.
    J Infect Dis. 2019 Nov 5. pii: 5613526. doi: 10.1093.
    PubMed     Abstract available


    October 2019
  44. ROSS S, Pati P, Jensen TL, Goll JB, et al
    Cytomegalovirus genetic diversity following primary infection.
    J Infect Dis. 2019 Oct 8. pii: 5583881. doi: 10.1093.
    PubMed     Abstract available


    April 2019
  45. EL HADDAD L, Ariza-Heredia E, Chemaly RF
    Reply to Gimenez et al.
    J Infect Dis. 2019;219:1512-1513.
    PubMed    


    February 2019
  46. BARANIAK I, Kern F, Holenya P, Griffiths P, et al
    Original antigenic sin shapes the immunological repertoire evoked by HCMV gB-MF59 vaccine in seropositive recipients.
    J Infect Dis. 2019 Feb 27. pii: 5366424. doi: 10.1093.
    PubMed     Abstract available


    January 2019
  47. MUENCHHOFF M, Adland E, Roider J, Kloverpris H, et al
    Differential Pathogen-Specific Immune Reconstitution in Antiretroviral Therapy-Treated Human Immunodeficiency Virus-Infected Children.
    J Infect Dis. 2019 Jan 8. pii: 5280900. doi: 10.1093.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Cytomegalovirus Infection is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: